Billionaire Stanley Druckenmiller Dumped 2 of His Top Performers -- Teva and Taiwan Semiconductor -- and Made This Sector-Based ETF His Fund's New No. 2 Holding

By Sean Williams – Mar 4, 2026 at 4:06AM ESTKey PointsForm 13Fs help investors track which stocks and exchange-traded funds (ETFs) Wall Street's most successful money managers bought and sold in the latest quarter. Profit-taking looks to have been on billionaire Stanley Druckenmiller's mind when he notably reduced his fund's stakes in Teva Pharmaceutical and Taiwan Semiconductor in the fourth quarter. Meanwhile, Duquesne's billionaire boss piled into a sector ETF that's highly sensitive to interest rate shifts.Two weeks ago, on Feb. 17, institutional investors with at least $100 million in assets under management were required to file Form 13F with regulators. A 13F is an invaluable data set that allows investors to track which stocks and exchange-traded funds (ETFs) Wall Street's preeminent money managers bought and sold in the latest quarter.

Following Warren Buffett's retirement, Stanley Druckenmiller of Duquesne Family Office is, arguably, Wall Street's savviest billionaire investor. According to Duquesne's 13F, its billionaire boss was a decisive seller of two top-performing stocks during the fourth quarter -- Teva Pharmaceutical Industries (TEVA 4.32%) and Taiwan Semiconductor Manufacturing (TSM 4.32%), commonly known as "TSMC" -- and a big-time buyer of an ultra-popular sector-based ETF. Image source: Getty Images.

Billionaire Stanley Druckenmiller is paring down two of his biggest winners According to Duquesne's latest 13F filing, Druckenmiller reduced his fund's position in Teva Pharmaceutical by 10,719,065 shares (a 65% cut) and sent 222,000 shares of TSMC to the chopping block (a 29% reduction). If you're wondering why one of Wall Street's most prominent billionaire money managers is heading for the exit, look no further than the respective outperformance of these two stocks. ExpandNYSE: TEVATeva Pharmaceutical IndustriesToday's Change(-4.32%) $-1.46Current Price$32.31Key Data PointsMarket Cap$37BDay's Range$31.71 - $32.8652wk Range$12.46 - $37.34Volume308KAvg Vol9.4MGross Margin51.82% Shares of Teva have effectively doubled since Druckenmiller began building a sizable position during the third quarter of 2024. Under CEO Richard Francis, Teva has placed more emphasis on higher-margin novel drug development, which has translated into stronger sales growth. This boost in the company's top-line comes after years of cost-cutting and non-core asset sales that have meaningfully improved the financial flexibility of Teva's balance sheet. Meanwhile, Taiwan Semiconductor stock has more than doubled since Druckenmiller opened a position (also in the third quarter of 2024). TSMC is the world's leading chip fabricator and an undeniable beneficiary of the artificial intelligence (AI) revolution. TSMC's chip-on-wafer-on-substrate technology, which packs high-bandwidth memory with graphics processing units, is an AI-accelerated data center staple. With the average security in Duquesne's $4.5 billion investment portfolio only held for 7.5 months, it's no surprise to see its billionaire boss ringing the register. Image source: Getty Images. Financials are the new apple of Druckenmiller's eye Perhaps the biggest surprise of Duquesne's 13F was the 5,495,600 shares purchased of the State Street Financial Select Sector SPDR ETF (XLF 0.17%). In simpler terms, Druckenmiller purchased a security that represents the financial sector components of the benchmark S&P 500 -- and he made it his fund's No. 2 holding. Investors typically buy into a financial sector ETF to take advantage of cyclical upside. Banks and insurance companies tend to ebb and flow with the health of the U.S. economy. With U.S. gross domestic product expanding, this roughly $301 million purchase by Druckenmiller may signal optimism in the U.S. economy and for lenders. ExpandNYSEMKT: XLFSelect Sector SPDR Trust - State Street Financial Select Sector SPDR ETFToday's Change(-0.17%) $-0.09Current Price$51.21Key Data PointsDay's Range$50.08 - $51.5552wk Range$42.21 - $56.52Volume3.8K However, optimism usually peaks with the State Street Financial Select Sector SPDR ETF when interest rates are rising. Higher rates lead to more profitable loan originations and higher interest income for financial institutions. Yet, the Federal Reserve has been in a rate-easing cycle since September 2024. It's also possible that Duquesne's billionaire investor is concerned about inflation and the possibility that interest rates will stabilize or even rise. If the central bank were to reverse course, financial stocks would be sitting pretty.Read NextMar 14, 2023 •By Matt Frankel, CFP3 Top-Notch Bank ETFs to Buy Right NowFeb 24, 2021 •By Billy Duberstein3 Reasons These Stocks Could Be Headed HigherAug 27, 2020 •By Matt Frankel, CFP2 Financial Stocks on My RadarAug 26, 2020 •By Matt Frankel, CFPWorried About Another Crash?

Buy Goldman SachsJul 22, 2020 •By Matt Frankel, CFPWells Fargo Is One of the Most Popular Bank Stocks on Robinhood.

Should It Be?Jun 3, 2020 •By Matt Frankel, CFPHere's Why Wells Fargo, JPMorgan Chase, and Other Big Banks Are Soaring on WednesdayAbout the AuthorSean Williams is a data-driven Motley Fool contributing analyst who's been investing for 27 years and has penned north of 15,000 articles. You'll find him at the intersection of politics and investing tackling macroeconomic topics of interest (Social Security and Donald Trump's economic/tax policies), analyzing which stocks billionaire investors (e.g., Warren Buffett) are buying and selling, and digging into how the world's most-influential businesses and trends -- everything from the evolution of artificial intelligence (AI) to the next stock split -- are changing Wall Street. He holds a B.A. in Economics from the University of California, San Diego.TMFUltraLongX@AMCScamStocks MentionedSelect Sector SPDR Trust - State Street Financial Select Sector SPDR ETFNYSEMKT: XLF$51.21(-0.17%)-$0.09Taiwan Semiconductor ManufacturingNYSE: TSM$353.18(-4.32%)-$15.93Teva Pharmaceutical IndustriesNYSE: TEVA$32.31(-4.32%)-$1.46*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.